Acutus Medical Interview Questions

Never Before Have Physicians Seen Such a Clear Picture of Real-Time Heart Function

We spoke with Oxford Heart Centre Cardiologist Dr. Timothy Betts about how Acutus has given him a clear vision for the treatment of AF.

Watch an AF procedure by Dr. Betts at the Radcliffe Hospital, Oxford England using the AcQMap System.

David Roman: Sure, absolutely. So I’ve been at Acutus now just about 18 months, I joined in March of 2021 as our CFO and was promoted to President and CEO in July of this year actually, it was on my birthday so it was a very nice birthday present from our board of directors, but I’m really excited to be in this role. Prior to joining Acutus, I spent five years at Baxter International in Chicago running strategy and FP&A for Baxter, and for the 12 years prior to that, I was a sell-side equity analyst covering the medical device space. I spent four years at Morgan Stanley and eight years at Goldman Sachs and when I was at Goldman, I led the medical device research team. I have lived, breathed, and slept at this space for a very long time and my depth of experience in the industry from a strategy and market perspective gives me great confidence in Acutus’ future, and this is just a fantastic opportunity.

WSA: Right, yeah, you don’t want to get the Oscar music, when you’re accepting the award and trying to thank everyone.

David Roman: Yeah, so I would say there are three things I’d point to. Firstly, we operate in a large attractive and growing market where there’s every reason to believe that this category is going to continue to grow at a double-digit rate for the foreseeable future. Second, we have a truly differentiated technology that we have launched, iterated and are refining now to significantly accelerate the adoption of that technology. And then third, we have made significant changes to this organization to create a strong and viable growth platform for the next several years. A lot of that restructuring and reorganization is moving into the rearview mirror, and our future looks brighter than ever. I have never felt as good about the company as I do right now and I think investors here have a fantastic opportunity to enter a stock price that is severely depressed for a variety of reasons, some of which is macro, some of which is company related, but where all of that is sun-setting, and we start to move into a period of more attractive growth that will reward all of our stakeholders, investors, employees, physicians, and other industry participants. So I think now is a great time to enter the story ahead of some significant news flow, as well as investing in a new management team, who is committed to execution and the creation of shareholder value.

WSA: Well, we certainly look forward to continuing to track the company’s growth and report on the upcoming progress. And we’d like to thank you for taking the time to join us today, David, and introduce our investor audience to Acutus, to AFIB. It was great having you on.

WSA: Good day from Wall Street, this is Juan Costello, Senior analyst with The Wall Street Analyzer. Joining us today is David Roman, CEO for Acutus Medical. The company trades on NASDAQ ticker symbol AFIB. Thanks for joining us today, David.

Acutus HRS 2022 Rhythm Theater Presentation

Related Posts

Leave a Reply

Your email address will not be published. Required fields are marked *